Oscient Pharmaceuticals Corporation (GENE)
Interview with: Steven M. Rauscher, President and CEO
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their FACTIVEŽ (gemifloxacin
mesylate) tablets for community-acquired pneumonia of mild to moderate severity and acute
bacterial exacerbations of chronic bronchitis. |
Cover Story
CEOCFO
Interview Index
CEOCFO
Current Issue
Cover Story
Archives
Future Features
Analyst Interviews
Corporate
Financials
Archived Interviews
About CEOCFOinterviews.com
Contact
& Ordering |
This is a printer friendly page!
With its FACTIVEŽ product approved
by the FDA and its Ramoplanin
product in late-stage clinical trials, Oscient
Pharmaceuticals is ready to arm physicians with the next weapons in the fight against community-and hospital-acquired infections
Healthcare
Biotechnology
(GENE-NASDAQ)
Oscient Pharmaceuticals Corporation
Steven M. Rauscher
President and CEO
Interview conducted by:
Lynn Fosse
Senior Editor
CEOCFOinterviews.com
May 2004
Instant Access:
To view a copy of this highly informative interview, left click here: ViewGENE
disclaimer
|
